In patients with high-risk factors (such as late clinical stage, >6 lymph node metastases, vascular tumor thrombus, nerve invasion, and HER2 overexpression), the follow-up frequency can be increased to six months or three months. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.